Clin2
NCT03356808Possibly a fitNot yet recruiting

Immune cell therapy for advanced lung cancer

Lung Cancer

Part of Cancer, Lungs & breathing clinical trials.

This trial tests a personalized immune cell therapy for advanced or relapsed lung cancer. Doctors take your blood, create special T cells that target unique proteins on your cancer, and give them back to you to try to fight the tumor.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
20 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You must have stage III, IV, or relapsed lung cancer that has been confirmed by a biopsy.
  • You need to be between 18 and 80 years old.
  • It should be at least 4 weeks since your last chemotherapy or radiation, and at least 2 weeks since you stopped taking steroids or other immune-suppressing drugs.
  • Your tumor must have high levels of certain cancer-specific proteins (antigens) that can be targeted by the immune cells.
  • You should be in generally good health, with acceptable blood counts, liver and kidney function, and oxygen levels above 90%.
  • You cannot have other serious health issues like active infections, heart problems, or a history of seizures.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04842812Recruiting· Phase 1
Personalized immune cell therapy for advanced solid tumors

This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.

Guangzhou
NCT06538012Recruiting· Phase 1/Phase 2
Tumor immune cells plus pembrolizumab for advanced lung cancer

This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.

Beijing, Beijing Municipality
NCT03778814Recruiting· Phase 1
Personalized T-cell therapy for advanced lung or solid tumors

This Phase 1 study tests a lab-made immune cell treatment made from your own blood cells (T cells) to fight advanced lung cancer or other solid tumors. You may be eligible if your tumor can be biopsied and the lab can successfully prepare T cells that strongly recognize and attack your cancer.

Guanzhou, Guangdong
NCT07467863Recruiting· Phase 1/Phase 2
Gene-modified immune cells for advanced lung cancer

This trial tests an experimental immune cell therapy (CAR-NK cells) that targets two to three specific markers on your lung cancer cells. It may be an option if your cancer has stopped responding to standard treatments and if tests show your tumor carries those markers.

Shenzhen, Guangdong
NCT06455917Recruiting· Phase 2
Personalized immune cell therapy for advanced lung cancer

This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.

Basel, Canton of Basel-City
NCT07260058Not yet recruiting· Phase 1/Phase 2
Immune cell therapy for advanced solid tumors

This trial tests a new immune cell therapy for people with advanced solid tumors of the lung, liver, colon, rectum, or breast. It aims to see if the treatment is safe and can help shrink or control the cancer.

Hear when a new Lung cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.